Pharma channel feed

Up­dat­ed: US se­lects first 10 drugs sub­ject to Medicare price ne­go­ti­a­tions

Last year
FDA+

Re­silience part­ners with Sau­di-based Lif­era to build bio­man­u­fac­tur­ing site

Last year
Deals
Manufacturing

FDA to hold off on en­forc­ing some parts of ma­jor sup­ply chain law un­til 2024

Last year
FDA+

Al­ny­lam plans to ap­peal Covid-19 vac­cine patent rul­ing in case against Mod­er­na

Last year
Law

ABPI, re­searchers crit­i­cize NHS’ In­no­v­a­tive Med­i­cines Fund, with no new ther­a­pies avail­able over a year af­ter for­ma­tion

Last year

Mod­er­na high­lights ten­nis leg­end Arthur Ashe in sec­ond ‘Change Mak­ers’ cam­paign at US Open, ahead of fall vac­cine sea­son

Last year
Marketing

FTC paus­es chal­lenge of Am­gen's $28B Hori­zon takeover to con­sid­er set­tle­ment

Last year
Law

Sanofi flies new flag for menin­gi­tis aware­ness, mark­ing one year to the Paris Par­a­lympics with three Team Sanofi ath­letes

Last year
Marketing

Phar­ma en­ters ‘age of un­cer­tain­ty’ amid chal­lenges from IRA, FTC and patent cliffs

Last year

FDA pub­lish­es On­copep­tides’ with­draw­al ap­peal for Swedish biotech’s can­cer drug Pepax­to

Last year
FDA+

Am­gen rais­es ‘bad’ cho­les­terol con­cerns in cam­paign with Amer­i­can Heart As­so­ci­a­tion

Last year
Marketing

HHS, vac­cine mak­ers prep for first-ever three-vac­cine avail­abil­i­ty with Covid, flu and RSV ahead of peak vi­ral sea­son

Last year
Marketing

As­traZeneca dis­putes IRA’s or­phan drug pro­vi­sions in lat­est le­gal chal­lenge to the law

Last year
FDA+
Law

FDA ap­proves San­doz’s na­tal­izum­ab biosim­i­lar, like­ly putting a damper on Bio­gen’s Tysabri sales

Last year
FDA+

CMS’ Medicare ne­go­ti­a­tion list is com­ing next week. Here’s what to ex­pect

Last year
FDA+

CA fed­er­al judge al­lows for­mer em­ploy­ee's case against So­ma­Log­ic to con­tin­ue

Last year
Law

CVS Health goes in­to the biosim­i­lar mar­ket with new sub­sidiary

Last year
Manufacturing

Ab­b­Vie drops two ear­ly-stage AD­Cs, in­clud­ing Pfiz­er-part­nered on­col­o­gy pro­gram

Last year
R&D

In PhI­II da­ta, Eli Lil­ly’s Retev­mo meets pri­ma­ry end­point of im­prov­ing pro­gres­sion-free sur­vival

Last year
R&D

FDA ad­vi­so­ry com­mit­tee will meet next month to dis­cuss Intar­ci­a's di­a­betes drug

Last year
FDA+

Mallinck­rodt signs re­struc­ture agree­ment with cred­i­tors, plans to file for bank­rupt­cy

Last year

Bris­tol My­ers touts ear­ly so­cial and en­vi­ron­men­tal progress among achieve­ments in lat­est ESG re­port

Last year
Marketing

GSK asks US patent of­fice to refuse Mod­er­na’s ‘Covid Mvax’ trade­mark reg­is­tra­tion as 'too gener­ic'

Last year
Marketing

Biden awards $24M to de­vel­op mR­NA tech tar­get­ing can­cer, oth­er dis­eases

Last year
R&D
FDA+
First page Previous page 104105106107108109110 Next page Last page
A service from the Financial Times